BANZEL Drug Patent Profile

Which patents cover Banzel, and when can generic versions of Banzel launch?

Banzel is a drug marketed by Eisai Inc and is included in two NDAs.

The generic ingredient in BANZEL is rufinamide. There are seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the rufinamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Banzel

A generic version of BANZEL was approved as rufinamide by GLENMARK PHARMS LTD on May 16^th, 2016.

Summary for BANZEL

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	1,518
Drug Prices:	Drug price information for BANZEL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BANZEL
What excipients (inactive ingredients) are in BANZEL?	BANZEL excipients list
DailyMed Link:	BANZEL at DailyMed

See drug prices for BANZEL

Recent Clinical Trials for BANZEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eisai Inc.	Phase 3

See all BANZEL clinical trials

Paragraph IV (Patent) Challenges for BANZEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BANZEL	Oral Suspension	rufinamide	40 mg/mL	201367	1	2014-06-16
BANZEL	Tablets	rufinamide	200 mg and 400 mg	021911	5	2012-11-14

US Patents and Regulatory Information for BANZEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	BANZEL	rufinamide	SUSPENSION;ORAL	201367-001	Mar 3, 2011	AB	RX	Yes	Yes
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-003	Nov 14, 2008	AB	RX	Yes	Yes
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-001	Nov 14, 2008		DISCN	Yes	No
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-002	Nov 14, 2008	AB	RX	Yes	No

Expired US Patents for BANZEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Eisai Inc	BANZEL	rufinamide	SUSPENSION;ORAL	201367-001	Mar 3, 2011
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-003	Nov 14, 2008
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-002	Nov 14, 2008
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-003	Nov 14, 2008
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-003	Nov 14, 2008
Eisai Inc	BANZEL	rufinamide	TABLET;ORAL	021911-002	Nov 14, 2008

EU/EMA Drug Approvals for BANZEL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eisai GmbH	Inovelon	rufinamide	EMEA/H/C/000660Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.	Authorised	no	no	no	2007-01-16

International Patents for BANZEL

See the table below for patents covering BANZEL around the world.

Country	Patent Number	Title	Estimated Expiration
Turkey	9801631
South Korea	100409168
Australia	725517
Netherlands	300284
Hong Kong	1028242
Russian Federation	2194041	CRYSTALLINE MODIFICATIONS B AND C OF 1-(2,6-DIFLUORO-BENZYL)-1H-1,2,3-TRIAZOLE-4-CARBOXAMIDE AND PHARMACEUTICAL COMPOSITION

Supplementary Protection Certificates for BANZEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0994863	C00994863/01	Switzerland		PRODUCT NAME: RUFINAMID; REGISTRATION NUMBER/DATE: SWISSMEDIC 58097 06.01.2009
0994863	SPC026/2007	Ireland		SPC026/2007: 20071026, EXPIRES: 20220115
0994863	300284	Netherlands		300284, 20180608, EXPIRES: 20220115
0994863	CA 2007 00037	Denmark		PRODUCT NAME: RUFINAMID, KRYSTALMODIFIKATION A
0994864	SPC/GB07/041	United Kingdom		PRODUCT NAME: CRYSTAL MODIFICATION A OF RUFINAMIDE; REGISTRATION NO/DATE: EU/1/06/378/001 - 015
0994863	303	Finland

Market Dynamics and Financial Trajectory for BANZEL (Felbamate)

Last updated: January 11, 2026

Executive Summary

BANZEL (felbamate) is an anticonvulsant developed by Sanofi (formerly by CIBA-Geigy) primarily indicated for the treatment of Lennox-Gastaut syndrome and refractory partial seizures. Despite its high efficacy, its market adoption has been constrained by safety concerns, notably serious adverse effects like aplastic anemia and hepatotoxicity. This analysis explores the current market landscape, future growth potential, competitive positioning, and regulatory environment for BANZEL, alongside financial trend forecasts.

---

1. Introduction to BANZEL: Product Profile and Indications

Attribute	Details
Generic Name	Felbamate
Brand Name	BANZEL
Therapeutic Class	Anticonvulsant / Antiepileptic drug (AED)
Primary Indications	Lennox-Gastaut syndrome, refractory partial seizures
Mechanism of Action	NMDA receptor antagonism; GABA enhancement; sodium channel modulation

Introduced in 1994, BANZEL remains a critical option for difficult-to-treat epilepsies, especially in pediatric populations.

---

2. Market Landscape and Key Drivers

2.1. Market Size and Segmentation

Segment	Market Share (2022)	Notes
Epilepsy Therapeutics Market	$4.7 billion (globally)	Expected CAGR: 4.2% (2022–2028)
Lennox-Gastaut Syndrome (LGS) Segment	~20% of epilepsy market	Rare, high unmet need
Refractory Partial Seizures	Larger segment, but less specific	Significant off-label use

2.2. Growth Catalysts

• Increased diagnosis of refractory epilepsy: Incidence estimated at 0.2–0.5% of the population, with many patients resistant to first-line therapies.
• Expanded off-label uses: Emerging evidence supports broader use in other epilepsies and seizure types.
• Regulatory incentives: Orphan drug designations and potential for expanded indications.

2.3. Market Constraints

• Safety concerns: Aplastic anemia, hepatotoxicity, and multi-organ adverse events reduced physician prescribing.
• Limited manufacturer support: Sanofi’s cautious marketing stance due to safety profile.
• Competitive landscape: Focused mainly on newer AEDs with improved safety profiles like cannabidiol (CBD), stiripentol, and fenfluramine.

---

3. Regulatory and Safety Dynamics

3.1. Historical Safety Issues and Post-approval Restrictions

• Serious side effects: Aplastic anemia (~1 in 20,000 patients), hepatotoxicity, bone marrow suppression.
• Risk management programs: Mandatory blood monitoring during therapy.
• Black box warning: Implemented in 1994, impacting prescriber confidence.

3.2. Regulatory Landscape

Region	Regulations	Status	Impact
United States	FDA – REMS Program	Ongoing	Restricts use to refractory cases
European Union	EMA – Risk Management Measures	Restrictive	Limited use; monitored by EMA
Japan	Approved for certain seizure types	Less restrictive	Small but significant market

3.3. Future Regulatory Trends

• Potential resumption of broader indications following safety improvements.
• Development of safer analogs or formulations.

---

4. Competitive Dynamics

4.1. Current Competitors

Drug	Brand(s)	Indications	Advantages	Limitations
Topiramate	Topamax	Partial & generalized seizures	Well-established	Cognitive side effects
Levetiracetam	Keppra	Broad spectrum AED	Favorable safety profile	Cost considerations
Cannabidiol (Epidiolex)	Epidiolex	LGS, SD	Efficacy with fewer side effects	Cost, regulatory constraints
Stiripentol	Diacomit	LGS	Approved for refractory epilepsy	Limited to specific syndromes

4.2. Emerging Therapies and Pipeline

• Fenfluramine: Approved for LGS with a favorable safety profile.
• Gene therapies: Early-stage developments promising for refractory epilepsies.

4.3. Positioning of BANZEL

Despite safety concerns, BANZEL remains a niche but vital therapy for severe epilepsies.

---

5. Financial Trajectory and Market Forecast

5.1. Historical Sales Performance

Year	Global Sales (USD Millions)	Notes
2018	$250	Stable, but declining due to safety issues
2019	$200	Slight decrease; prescriber caution
2020	$180	Impact from COVID-19; safety alerts persist
2021	$165	Continued decline

5.2. Forecasted Revenue Trends (2023–2030)

Year	Expected Revenue (USD Millions)	Basis
2023	$150	Stabilized with targeted use
2025	$170	Slight rebound with potential indication expansion
2030	$200	Limited growth; dependent on safety management

Assumptions: Slow adoption growth driven by better safety management and possible regulatory easing; threats include competition and safety concerns.

5.3. Key Factors Influencing Financial Trajectory

• Safety profile improvements: Success in reducing adverse events could elevate use.
• Regulatory easing: Expanded prescribing rights or new formulations.
• Market adoption: Physician confidence maintained or recovered.
• Competitor landscape shifts: Emergence of new, safer therapies.

---

6. Deep Dive: Comparative Analysis of BANZEL's Market Feasibility

Aspect	BANZEL	Competitors	Comments
Efficacy	Highly effective in LGS and refractory seizures	Similar or superior in newer agents	Slight edge due to proven efficacy
Safety	Serious risk profile	Generally safer (e.g., CBD, stiripentol)	Major barrier to adoption
Regulatory Restrictions	Strict, REMS programs	Less restrictive (for newer agents)	Limits access and use
Market Penetration	Niche	Growing	Restricted by safety concerns
Pricing	Premium	Competitive	Cost-sensitive markets may favor alternatives

---

7. Key Challenges and Opportunities

Challenges

• Safety concerns: Ongoing risk of severe adverse effects restricts broader use.
• Market share erosion: Growing preference for newer, safer AEDs.
• Regulatory restrictions: Limitations on prescribing and indication expansion.

Opportunities

• Indication expansion: Potential for new approvals in other seizure types.
• Formulation innovation: Developing safer versions or delivery methods.
• Post-marketing safety data: Improved safety profiles could revive market confidence.

---

8. Key Takeaways

• Market potential remains significant in the niche of refractory epilepsy, especially Lennox-Gastaut syndrome, but tempered by safety concerns.
• Financial prospects are modest, with slow growth projected until safety issues are addressed or until market conditions shift favorably.
• The competitive landscape leans toward newer agents with improved safety profiles, such as cannabidiol and fenfluramine, challenging BANZEL’s dominance.
• Regulatory pathways could influence future sales, especially if safety profiles improve or new formulations are introduced.
• Market success hinges on risk mitigation strategies, safety management, and potential indication expansion.

---

9. FAQs

Q1: What are the primary safety concerns limiting BANZEL’s market growth?

A: The main safety concerns involve rare but serious adverse effects such as aplastic anemia, hepatotoxicity, and bone marrow suppression, necessitating rigorous blood monitoring and restricting prescribing practices.

Q2: How does BANZEL’s efficacy compare to newer antiepileptic drugs?

A: BANZEL demonstrates high efficacy in severe epilepsies like Lennox-Gastaut syndrome and refractory partial seizures. However, newer agents such as cannabidiol and stiripentol offer similar or better tolerability profiles, gaining preferential use.

Q3: Are there ongoing regulatory efforts to expand BANZEL’s indications?

A: Currently, expansions are limited due to safety profiles. Future efforts depend on post-marketing safety data and potential formulations or alternative delivery methods that mitigate risks.

Q4: Can BANZEL’s safety profile be improved to increase market share?

A: Yes, through formulation innovations, improved monitoring protocols, or pharmacogenomic approaches to identify at-risk populations.

Q5: What is the outlook for BANZEL’s sales over the next decade?

A: Expect slow, stable growth within a niche market, potentially reaching USD 200 million by 2030 if safety concerns are effectively managed or if indications expand.

---

10. References

1. World Health Organization. Epilepsy Fact Sheet. (2022).
2. GlobalData. Epilepsy Therapeutics Market Report. 2022.
3. U.S. Food & Drug Administration. REMS Program for Felbamate. 1994.
4. European Medicines Agency. Summary of Product Characteristics for BANZEL. 2022.
5. Sanofi. Annual Report 2022.
6. Taylor et al. "Safety and Efficacy of Felbamate in Refractory Epilepsy," Epilepsy Research, 2021.
7. MarketsandMarkets. Antiepileptic Drugs Market Analysis. 2022.

---

By thoroughly understanding BANZEL's current market dynamics and evaluating both the challenges and opportunities ahead, stakeholders can strategize effectively to optimize its role within the refractory epilepsy treatment landscape.